Clinical Significance Of Anti-streptolysin O And Anti-DNA Enzyme B In Ankylosing Spondylitis Patients And The Association Between Rheumatoid Arthritis With Tumor Necrosis Factor Receptor Ⅱ 196 Site Polymorphism By Meta-analysis

PartⅠClinical significance of anti-streptolysin O and anti-DNA enzyme B in patients with ankylosing spondylitisAnkylosing spondylitis (AS) is a chronic progressive inflammatory disease and characterized by pathological changes are attached to tendons and ligaments.The point of chronic inflammation in some patients accompanied by varying degrees of eye, lung, cardiovascular, kidney and other diseases.The cause is unclear now. Genetic factors, environmental factors and immune factors, have may be related to the pathogenesis of AS.ObjectiveTo investigate clinical significance in patients of ankylosing spondylitis (AS) with anti-streptolysin O (ASO) and anti-DNA enzyme B(ADB).Methods1.Review 159 cases of ankylosing spondylitis patients, whether the increase will be in accordance with ASO were divided into two groups, simultaneous detection of HLA-B27, ESR, CRP and other laboratory indicator and record the temperature, observation of clinical signs and symptoms and image dgree. compare significant difference between the two groups.2. Anti-DNA enzyme B(ADB) and antistreptolysin O(ASO) in sera of 65 patients with ankylosing spondylitis and 96 cases of healthy controls were examined by enzyme-linked immunosorbent assay (ELISA).The ankylosing spondylitis patients were divided into two groups according to anti-DNA enzyme B being positive or negative, then contrasted and clinical analysis.Results1.In ASO-positive group of ankylosing spondylitis patients,the incidence of fever, ESR, peripheral joint pain, "4" character and Schober test were significantly higher than ASO-negative group.(all P＜0.05)2. The positive rate of ASO in ankylosing spondylitis patients group was 47.7%,and the healthy control group was 24.0%, the two groups was statistically different (P <0.05); The positive rate of ADB in ankylosing spondylitis patients group was 58.5%,and the healthy control group was 28.0%, the two groups was statistically different (P<0.005). There was no significant difference for detecting ADB and ASO in ankylosing spondylitis patients (P> 0.05).3. The average ages of ADB positive group were significantly lower than negative group in ankylosing spondylitis patients(P<0.05).In ankylosing spondylitis patients of ADB positive group,the knee,ankle swelling and pain, hip pain, "4" sign-positive, WBC were significantly higher than the negative group (P<0.05). The spinal activity of ADB positive group in ankylosing spondylitis patients were significantly lower than the negative group (P<0.05). ADB positive group of ankylosing spondylitis patients with spinal pain score, Bath Ankylosing Spondylitis Disease Activity Index(BASDAI), Bath Ankylosing Spondylitis Functional Index(BASFI) and ESR were significantly higher than the negative group (P<0.05).Conclusions1. The incidence in ankylosing spondylitis patients with hemolytic streptococcus infection is higher than normal.2. The condition of ASO and ADB positive groups in ankylosing spondylitis patients are more worse than the negative group.3. There have association between streptococcal infection and ankylosing spondylitis patients disease activity.4. Streptococci may be involved in the occurrence and development of ankylosing spondylitis. PartⅡThe association between rheumatoid arthritis with tumor necrosis factor receptorⅡ196 gene site polymorphism by meta-analysisObjectiveTo investigate the association between the tumor necrosis factor receptorⅡposition 196 (TNFRⅡ196) gene polymorphism and patients with rheumatoid arthritis (RA).MethodsWe performed a meta-analysis of the published literatures on the TNFRⅡposition 196 gene polymorphism and RA with Review Manager 4.2.ResultsA total of nine literatures involving 2140 cases and 1297 controls were included. Comprehensive analysis showed that there was no association between TNFRⅡ196 alleles, TNFRⅡ196TG, GG genotype and RA, (OR=1.11; 95% CI=0.91-1.34; P=0.32 for TNFRⅡ196 alleles; OR=1.38; 95% CI=0.97-1.98; P=0.07 for TNFRⅡ196TG genotype; and OR=1.09; 95% CI=0.93-1.27; P=0.31 for TNFRⅡ196GG genotype. However, an association between TNFRⅡ196 alleles and TNFRⅡ196GG genotype and familial RA was found (OR=1.43; 95% CI= 1.11-1.86; P=0.006 for TNFRⅡ196 alleles and OR=2.68; 95% CI=1.39-5.17; P=0.003 TNFRⅡ196GG genotype, respectively), but not between TNFRⅡ196TG genotype and familial RA (OR=1.00; 95% CI=0.71-1.39; P=0.98). Finally we found no association between the TNFRⅡ196 alleles, TNFRⅡ196GG, TG genotype and Sporadic RA (OR=1.13; 95%CI=0.89-1.44; P=0.32 for TNFRⅡ196 alleles; OR=1.44; 95% CI= 0.75-2.76; P=0.27 for TNFR II 196GG genotype; and OR=1.03; 95% CI=0.76-1.39; P=0.86 for TNFRⅡ196TG genotype).Conclusions1. The analysis by Meta showed that TNFRⅡ196 site polymorphism and the GG genotype may be associated with familial RA patients.2. The TNFRⅡ196 alleles and the GG genotype might be associated with familial not sporadic RA.